-
Ultimovacs ASA: Second quarter 2020 result presentation
-
Ultimovacs ASA Announces Completion of Patient Enrollment in Phase I Trial in Malignant Melanoma
-
Ultimovacs ASA: Invitation to second quarter 2020 results webcast presentation
-
Ultimovacs ASA Announces First Patient Dosed in the Phase II INITIUM Trial in Metastatic Malignant Melanoma
-
Ultimovacs ASA Announces First Patient Enrolled in the NIPU Phase II Clinical Trial Testing UV1 Against Mesothelioma
-
Ultimovacs ASA – New share capital registered
-
Ultimovacs ASA – Private placement of new shares successfully placed
-
Ultimovacs ASA – Contemplated private placement
-
Ultimovacs ASA Announces Collaboration with Big Pharma Company and Leading European Oncology Clinical Trial Group to Evaluate UV1 in a Third Phase II Clinical Trial
-
Ultimovacs ASA – Share Option Program
